Progranulin mutations in clinical and neuropathological Alzheimer's disease
Badri N. Vardarajan, Dolly Reyes‐Dumeyer, Angel Piriz, Rafael Lantigua, Martin Medrano, Diones Rivera, Ivonne Z. Jiménez‐Velázquez, Eden R. Martin, Margaret A. Pericak‐Vance, William S. Bush, Lindsay A. Farrer, Jonathan L. Haines, Weixin Wang, Yuk Yee Leung, Gerard D. Schellenberg, Walter A. Kukull, Philip L. De Jager, David A. Bennett, Julie A. Schneider, Alzheimer's Disease Sequencing Project, Richard Mayeux
Abstract
INTRODUCTION: Progranulin (GRN) mutations occur in frontotemporal lobar degeneration (FTLD) and in Alzheimer's disease (AD), often with TDP-43 pathology. METHODS: We determined the frequency of rs5848 and rare, pathogenic GRN mutations in two autopsy and one family cohort. We compared Braak stage, β-amyloid load, hyperphosphorylated tau (PHFtau) tangle density and TDP-43 pathology in GRN carriers and non-carriers. RESULTS: Pathogenic GRN mutations were more frequent in all cohorts compared to the Genome Aggregation Database (gnomAD), but there was no evidence for association with AD. Pathogenic GRN carriers had significantly higher PHFtau tangle density adjusting for age, sex and APOE ε4 genotype. AD patients with rs5848 had higher frequencies of hippocampal sclerosis and TDP-43 deposits. Twenty-two rare, pathogenic GRN variants were observed in the family cohort. DISCUSSION: GRN mutations in clinical and neuropathological AD increase the burden of tau-related brain pathology but show no specific association with β-amyloid load or AD.